Cas:1245646-80-3 tert-Butyl 6-oxopiperidin-3-ylcarbamate manufacturer & supplier

We serve Chemical Name:tert-Butyl 6-oxopiperidin-3-ylcarbamate CAS:1245646-80-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

tert-Butyl 6-oxopiperidin-3-ylcarbamate

Chemical Name:tert-Butyl 6-oxopiperidin-3-ylcarbamate
CAS.NO:1245646-80-3
Synonyms:tert-butyl N-(6-oxopiperidin-3-yl)carbamate
Molecular Formula:C10H18N2O3
Molecular Weight:214.26200
HS Code:2933790090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:67.43000
Exact Mass:214.13200
LogP:1.50940

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like tert-butyl N-(6-oxopiperidin-3-yl)carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl N-(6-oxopiperidin-3-yl)carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl N-(6-oxopiperidin-3-yl)carbamate Use and application,tert-butyl N-(6-oxopiperidin-3-yl)carbamate technical grade,usp/ep/jp grade.


Related News: This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. tert-Butyl 6-oxopiperidin-3-ylcarbamate manufacturer Health officials said it remained unclear where he had developed the disease. tert-Butyl 6-oxopiperidin-3-ylcarbamate supplier Health officials said it remained unclear where he had developed the disease. tert-Butyl 6-oxopiperidin-3-ylcarbamate vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. tert-Butyl 6-oxopiperidin-3-ylcarbamate factory Health officials said it remained unclear where he had developed the disease.